Preclinical services for biopharmaceutical product development: IDIQ parent contract
Active Indefinite Delivery Contract Awarded
- Contract number
- 75N93023D00008
- Awardee
-
Dynport Vaccine Company LLC UEI LXNEGTYDR755 Part of General Dynamics Corp
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Preclinical services for biopharmaceutical product development Pre-Solicitation · 75N93022R00004 · Posted Nov 10, 2021
- Last date to order 44% complete
- IDV ceiling
- $30,000,000.00
- Maximum order
- $30,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single-award Indefinite Delivery Contract to Dynport Vaccine Company LLC with a potential value of $30 million. The contract provides preclinical services for biopharmaceutical product development across five task areas from 2023 through 2030.
Task areas include product development planning and evaluation, analytical assay development and product characterization, process development and related activities, CGMP manufacture and related activities, and regulatory activities and documentation. Services will support the assessment, development, production, and regulatory submission of biopharmaceutical therapeutics and diagnostics for infectious diseases. The goal is to provide critical preclinical data and assist in acquiring additional funding, partnerships, and regulatory approvals to advance promising candidates through early-stage development.
All work will be conducted in accordance with quality and safety standards for the appropriate development phase, including applicable federal and state regulations. Subcontracting will be permitted as needed to fulfill technical requirements.
Quick answers
Who was awarded contract 75N93023D00008?
75N93023D00008 was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 8, 2023.
How much is contract 75N93023D00008 worth?
75N93023D00008's own ceiling is $30,000,000. A single order can be worth up to $30,000,000.
Who can order from contract 75N93023D00008?
75N93023D00008 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N93023D00008 competed?
The extent of competition for 75N93023D00008 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV